---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Diagnosis"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Diagnosis. Topics: Diagnostic definition: high-risk genotype with nondiabetic kidney disease; Role of genotyping: definitive for risk alleles, not diagnostic of a specific disease; Delphi consensus: patients in whom APOL1-associated nephropathy should be considered; Delphi consensus: testing and kidney biopsy if a treatment becomes available; 10 further topics. 14 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/diagnosis"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Diagnostic definition: high-risk genotype with nondiabetic kidney disease

> “AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “A definitive diagnosis of AMKD requires a genetic test for the presence of two APOL1 risk variants.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.5-2"></a>

### Role of genotyping: definitive for risk alleles, not diagnostic of a specific disease

> “Genetic testing is definitive for the presence of APOL1 risk alleles, although the presence of risk alleles is not prognostic or diagnostic of any specific kidney diseases.”
> “However, for individuals, genotyping is an important clinical consideration given that the high-risk APOL1 genotypes are associated with significantly increased risk of CKD progression, and genotyping could inform risk stratification and frequency of follow-up.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.5-3"></a>

### Delphi consensus: patients in whom APOL1-associated nephropathy should be considered

> “A1. APOL1-associated nephropathy should be considered in all patients with kidney disease who have African ancestry, particularly when there is a family history of CKD”
> “A2. Regardless of ancestry, APOL1-associated nephropathy should be considered in all patients with kidney disease and a family member with a confirmed APOL1 high-risk genotype”
> “A3. Clinical factors that are relevant to considering APOL1-associated nephropathy include hypertension, nondiabetic nephropathy, and rapid progression of CKD”
> “A12. APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.5-4"></a>

### Delphi consensus: testing and kidney biopsy if a treatment becomes available

> “C3. If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling”
> “C4. If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling”
> “C6. If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.5-5"></a>

### Misclassification as hypertension-attributed CKD

> “Genetic testing for APOL1 in African ancestry patients with nephropathy is currently uncommon. As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Many with West African ancestry who have hypertension and kidney disease who were previously labeled as hypertensive nephropathy are now recognized to carry 2 APOL1 risk alleles and have APOL1-contributed kidney disease.”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

<a id="topic-2.2.1.5-6"></a>

### KDIGO Controversies Conference: principles for APOL1 testing

> “At population levels, there is insufficient evidence to guide recommendations for APOL1 routine testing or screening. There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.”
> “The individual has kidney disease OR is a prospective living kidney donor OR has a relative with an APOL1 high-risk genotype.”
> “Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.”
> “In children with FSGS and CKD, APOL1 genotyping can inform prognosis, and early targeted testing for APOL1 genotype in infants and children could make possible early surveillance and intervention.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.5-7"></a>

### Screening of asymptomatic individuals

> “Screening of asymptomatic individuals in the US for high-risk APOL1 genotype is not currently recommended.”
> “However, individuals with recent West African heritage who have nondiabetic CKD, proteinuria, or a family history of kidney disease may be offered APOL1 screening. All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.1.5-8"></a>

### KDIGO 2024 CKD guideline: genetic testing in evaluation of cause

| Test category | Examples | Comment |
| --- | --- | --- |
| Genetic testing | “APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, HNF1B, PKD1, PKD2” | “Evolving as a tool for diagnosis, increased utilization is expected.” |

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

> “Genetic testing is emerging as a valuable component for evaluation of cause.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.1.5-9"></a>

### Genotype refinement: the p.N264K (M1) protective variant

> “Therefore, this variant, based on prior functional and current genetic data, counters the toxic effect of the G2 allele, allowing the reclassifying of APOL1 high-risk individuals as non-high-risk if they carry the p.N264K missense variant.”

Source: [Gupta et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10689833/)

> “Among individuals with CKD with APOL1-HR genotypes, M1 was 4 times more frequent in those whose CKD was not due to FSGS or SRNS. Importantly, electronic health record and biopsy review identified an alternative, non-APOL1 cause for CKD in nearly all APOL1-HR-M1 cases.”
> “Patients with CKD with an APOL1-HR genotype and M1 should be evaluated for an alternative and potentially treatable cause of their CKD.”

Source: [Martinelli et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12980251/)

> “Therefore, risk prediction solely based on presence of APOL1 risk variants without testing for the N264K variant is inadequate.”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

<a id="topic-2.2.1.5-10"></a>

### Mendelian kidney disease in patients with high-risk genotypes

> “Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes. Among patients with recent genomic African ancestry, the prevalence of Mendelian kidney diseases was lower in those with high-risk APOL1 genotypes (9.6%; n = 91/944) compared with single risk APOL1 allele carriers (13.6%; n = 198/1453) and those with G0/G0 APOL1 genotypes (16.6%; n = 213/1281).”

Source: [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)

<a id="topic-2.2.1.5-11"></a>

### Unexplained kidney failure in the United Kingdom

> “Among individuals with recent African ancestry, high-risk APOL1 genotypes were significantly more common in those with uKF (52% vs 8.4% in those without uKF; P < 0.001).”

Source: [Sadeghi-Alavijeh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40967557/)

<a id="topic-2.2.1.5-12"></a>

### Living kidney donor evaluation

> “Among transplant centers in the United States, in 1 survey,93 one-half of centers offered APOL1 testing. The KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors94 suggests that APOL1 genotyping may be offered to donor candidates with Sub-Saharan African ancestry. The British Transplantation Society95 recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Therefore, in donors at high risk for APOL1 risk variants, genetic testing for APOL1 mutations may provide information for both the disease risk in the donor and allograft outcomes in the recipient.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

> “Healthy living donors who self-identify as Black people or of sub-Saharan or West African ancestry, who are otherwise approved for donation, should be counseled regarding the risk of future kidney disease from APOL1 G1 and G2 variants and the protective role of the N264K APOL1 variant and should also offered the option of testing (Supplementary Information, Case 4).”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

> “The study found that the APOL1 genotype is a risk factor for reduced kidney function postdonation. These results suggest that all Black individuals who are living donor candidates in the US should undergo APOL1 genotyping for better risk stratification.”

Source: [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)

> “Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.”

Source: [McIntosh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020447/)

<a id="topic-2.2.1.5-13"></a>

### Available tests: manufacturer-sponsored genotyping

> “This test is used for identification of APOL1 risk variants to aid the diagnosis and management of APOL1-mediated kidney disease (AMKD).”
> “Multiplex end-point TaqMan Polymerase Chain Reaction (PCR) allelic discrimination”
> “Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

> “Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease”

Source: [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)

<a id="topic-2.2.1.5-14"></a>

### Barriers to genetic testing

> “Barriers to widespread adoption of genetic testing include a lack of perceived benefit, lack of ease, difficulties in interpreting genetic variants, high cost, and the need for genetic counseling.”

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

Additional sources: [Mohan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6756958/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
